ENZ(Delisted)
Enzo Biochem (ENZ) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Enzo Biochem market cap is -- and enterprise value is --.
Share Statistics
Enzo Biochem has 52.40M shares outstanding, with a free float of 37.75M.
Valuation Ratios
Enzo Biochem's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Liquidity
Enzo Biochem's current ratio is 3.04, quick ratio is 2.69, and cash ratio is --, showing its short-term liquidity position.
Return on Capital
Enzo Biochem's ROE is --, ROA is --, and ROIC is --, showing its return on capital profile.
Profitability
Enzo Biochem gross margin is 44.74%, operating margin is -34.15%, and net margin is -73.25%.
Cost Structure
Enzo Biochem spends 7.75% of revenue on R&D and 65.63% on SG&A.
Operating Efficiency
Enzo Biochem's asset turnover is --, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.
Income Statement
Enzo Biochem's revenue is 29.09M, gross profit is 13.02M, net income is --, and EBITDA is --.
Balance Sheet
Enzo Biochem's total debt is --, net debt is --, total equity is --, and cash is --.
Cash Flow Statement
Enzo Biochem's operating cash flow is --, free cash flow is --, and CapEx is --.
Dividends & Yields
Enzo Biochem dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Enzo Biochem's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A developer of diagnostic and therapeutic products, Enzo Biochem focuses on molecular diagnostics, cancer research, and personalized medicine, with a portfolio of proprietary technologies
Per Share Metrics
Enzo Biochem's EPS is --, book value per share is --, and free cash flow per share is --.
